Retinal changes: a mortality risk in non-diabetics

Article

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

Despite retinopathy being fairly common among non-diabetics, its prognostic implications are not fully understood. Ronald Klein and colleagues from the University of Wisconsin, USA and the Federal University of Sao Paulo, Brazil hypothesized that retinal alterations are associated with increased mortality. In order to investigate this, they evaluated survival rates among 4,292 non-diabetic participants (age range, 43-84 years) of the Beaver Dam Eye Study.

Retinal photographs were used to classify retinopathy into four groups: no retinopathy, retinal haemorrhage only, retinal micro-aneurysm or moderate or worse retinopathy. Survival was analyzed over a 14-year follow-up period in five-year intervals.

The baseline prevalence of retinopathy was 7.6%. After the 14-year follow-up period it was discovered that moderate retinopathy, at baseline, increased the risk of all-cause mortality by 24% and ischaemic heart disease by more than three-fold.

Based on these results, the researchers believe that retinal changes do have possible prognostic implications regarding the survival of persons without diabetes.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.